Phencyclidine in the social interaction test: An animal model of schizophrenia with face and predictive validity

Reviews in the Neurosciences

Volumn 10, Issue 1, 1999, Pages 59-90

  Sams Dodd, Frank ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Animal model; Antipsychotics; Negative symptoms; Phencyclidine; Positive symptoms; Psychosis; Schizophrenia; Social behaviour

Indexed keywords

NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; NONHUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RAT; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; STEREOTYPY;

EID: 0032869421     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.1999.10.1.59     Document Type: Review

References (243)

1. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry 1998; 43: 811-816.
2. Aguayo LG, Warnick JE, Maayani S, Click SD, Weinstein H, Albuquerque EX. Site of action of phencyclidine. IV. Interaction of phencyclidine and its analogues on ionic channels of the electrically excitable membrane and nicotinic receptor: implications for behavioral effects. Mol Pharmacol 1982; 21: 637-647.
3. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135: 1081-1084.
4. Andreasen NC, Roy MA, Flaum M. Positive and negative symptoms. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford: Blackwell Science, 1994; 28-45.
5. Angrist B, Gershon S. The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Am J Psychiatry 1970; 2: 95-107.
6. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-asparatate. Br J Pharmacol 1983; 79: 565-575.
7. 3H)D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neurosci Lett 1997; 232: 13-16.
8. Amt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101.
9. Auerbach J, Hans S, Marcus J. Neurobehavioral functioning and social behavior of children at risk for schizophrenia. Isr J Psychiatr Rel Sci 1993; 30: 40-49.
10. Baba A, Yamamoto T, Kawai N, Yamamoto H, Suzuki T, Moroji T. Behavioral effects of phencyclidine and its major metabolite, (trans)4-phenyl-4-(1-piperidinyl) cyclohexanol, in mice. Behav Brain Res 1994; 65: 75-81.
11. Bailey DN, Shaw RF, Guba JJ. Phencyclidine abuse: plasma levels and clinical findings in casual users and in phencyclidine-related deaths. J Anal Toxicol 1978; 2: 233-237.
12. Bakker C, Amini F. Observations on the psychotomimetic effects of semyl. Comp Psychiatr 1961; 2: 269-280.
13. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995; 122: 198-201.
14. Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994; 271: 787-794.
15. Baldessarini R, Centorrino F, Flood J, Volpicelli S, Huston-Lyon D, Cohen B. Tissue concentrations of clozapine and its metabolites in the rat. Psychopharmacology 1993; 9: 117-124.
16. Ban T, Lohrenz J, Lehmann H. Observations on the action of sernyl - A new psychotropic drug. Can Psychiatr Assoc J 1961; 6: 150-157.
17. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett J, Neufeld RWJ. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997; 54: 959-965.
18. Beamish P, Kiloh L. Psychoses due to amphetamine consumption. J Ment Sci 1960; 106: 337-343.
19. Beasley J, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, Olanzapine H. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-167.
20. Bell D. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 1965; 111: 701-707.
21. Bell D. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 1973; 29: 35-40.
22. Bodi T, Share I, Levy H, Moyer J. Clinical trials of phencyclidine (sernyl) in patients with psychoneurosis. Antibio Med Clin Ther 1959; 6: 79-84.
23. Boer J, Megen H, Fleischhacker W, Louwerens J, Slaap B, Westenberg H, Burrows G, Srivastava O. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 1995; 121: 317-322.
24. Borison R, Diamond B, Sinha D, Gupta R, Ajiboye P. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988; 24: 260-263.
25. Boyce S, Rupniak NMJ, Steventon MJ, Cook G, Iversen SD. Psychomotor activity and cognitive disruption attributable to NMDA but not sigma interactions in primates. Behav Brain Res 1991; 42: 115-122.
26. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 1995; 674: 82-90.
27. Breier A, Buchanan R, Kirkpatrick B, Davis O, Irish D, Summerfelt A, Carpenter W. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-26.
28. Bunny B, Grace A. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 1978; 23: 1715-1728.
29. Byrd JC, Bykov V, Rothman R. Chronic haloperidol treatment up-regulates rat brain PCP receptors. Eur J Pharmacol 1987; 140: 121-122.
30. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 1990; 16: 425-432.
31. Casey D. Seroquel (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opion Inv Drugs 1996; 5: 939-957.
32. Castellani S, Adams P. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 1981; 73: 143-154.
33. Castellani S, Giannini AJ, Boeringa JA, Adams PM. Phencyclidine intoxication: assessment of possible antidotes. J Toxicol-Clin Toxicol 1982; 19: 313-319.
34. Chen G. Pharmacology of 1-(1-phenylcyclohexyl) piperidine,HCl. Fed Proc 1958; 17: 358 (abstr).
35. Cheng Y, Paalzow L. Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 1992; 13: 69-76.
36. Cho AK, Hiramatsu M, Pechnick RN, Di Stefano E. Pharmacokinetic and pharmacodynamic evaluation of phencyclidine and its decadeutero variant. J Pharmacol Exp Ther 1989; 250: 210-215.
37. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-39.
38. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS. Comparison of phencyclidine hydrochloride (sernyl) with other drugs. Arch Gen Psychiatry 1962; 6: 79-85.
39. Cohen LS, Gosenfeld L, Wilkins J, Kammerer RC, Tachiki K. Demonstration of an amino acid metabolite of phencyclidine [letter]. N Engl J Med 1982; 306: 1427-1428.
40. Collinge J, Curtis D. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Br J Psychiatry 1991; 159: 857-859.
41. Connell PH. Amphetamine Psychosis. London: Chapman & Hall, 1958.
42. Contreras PC, Rice KC, Jacobson AE. Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions. Eur J Pharmacol 1986; 121: 9-18.
43. Cook CE, Brine DR, Quin CD, Wall ME, Perez-Reyes M, Di Guiseppi SR. Smoking of phencyclidine: disposition in man and stability to pyrolytic conditions. Life Sci 1981; 29: 1967-1972.
44. Corbett R. Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol Biochem Behav 1995; 51: 561-564.
45. Corbett R, Camacho F, Woods A, Kerman L, Fishkin R, Brooks K, Dunn R. Antipsychotic agents antagonize non-competetive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology 1995; 120: 67-74.
46. Corbett R, Hartman H, Kerman L, Woods A, Strupczewski J, Helsley G, Conway P, Dunn R. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 1993; 45: 9-17.
47. Davies B, Beech H. The effects of 1-arylcyclohexylamine (sernyl) on twelve normal volunteers. J Ment Sci 1960; 106: 912-914.
48. De Angelis GG, Goldstein E. Treatment of adolescent phencyclidine (PCP) abusers. Am J Drug Alcohol Abuse 1978; 5: 399-414.
49. Deakin FW, Simpson MD, Slater P, Hellewell JS. Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia. J Psychopharmacol 1997; 11: 133-142.
50. Deakin JF, Simpson MD. A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J Psychiatr Res 1997; 31: 277-295.
51. Deakin JF, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52: 1781-1786.
52. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996; 58: 721-734.
53. Dodd F. Neural networks in pharmacology: Models of mental disorders and the effects of drug treatments. Nord J Psychiatry 1993; 47 (Suppl 28): 17-26.
54. Domino EF. History and pharmacology of PCP and PCP-related analogs. J Psychoactive Drug 1980; 12: 223-227.
55. Domino EF, Luby ED. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Cole JO, Freedman AM, Friedhoff AJ, eds. Psychopathology and Psychopharmacology. Baltimore, MD: Johns Hopkins University Press, 1973; 37-50.
56. Eastwood SL, Kerwin RW, Harrison PJ. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry 1997; 41: 636-643.
57. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 1995; 29: 211-223.
58. Eaton W, Tien A, Poeschla B. Epidemiology of schizophrenia. In: Den Boer JA, Westenberg HGM, Van Praag HM, eds. Advances in the Neurobiology of Schizophrenia. New York: Wiley, 1995; 27-57.
59. Ellenbroek B, Cools A. Animal models with construct validity for schizophrenia. Behav Pharmacol 1990; 1: 469-490.
60. Ellenbroek B, Willemen A, Cools A. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 1989; 2: 191-199.
61. Ellinwood E. Amphetamine psychosis: I. Description of the individuals and process. J Nerv Ment Dis 1967; 144: 273-283.
62. Ellison G. Competetive and non-competetive NMDA-antagonists induce similar limbic degeneration. Neuro-Report 1994; 5: 2688-2692.
63. Ellison G, Switzer R III. Dissimilar patterns of degeneration in brain following four different addictive stimulants. NeuroReport 1993; 5: 17-20.
64. Erard R, Luisada P, Peele R. The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J Psychactive Drug 1980; 12: 235-251.
65. Eriksson L. Remoxipride in the treatment of psychoses. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 619-623.
66. Farber N, Foster J, Duhan N, Olney J. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr Res 1996; 21: 33-37.
67. Farber N, Wozniak D, Price M, Labruyere J, Huss J, St Peter H, Olney J. Age-specfic neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 1995; 38: 788-796.
68. Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, Wozniak DF, Olney JW. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 1993; 34: 119-121.
69. Fauman B, Aldinger G, Fauman M, Rosen P. Psychiatric sequelae of phencyclidine abuse. Clin Toxicol 1976; 9: 529-538.
70. Fauman BJ, Fauman MA. Chronic phenycyclidine (PCP) abuse: a psychiatric perspective - Part II: Psychosis (proceedings). Psychopharmacol Bull 1980; 16: 72-73.
71. Fauman MA, Fauman BJ. The psychiatric aspects of chronic phencyclidine use: a study of chronic PCP users. Washington, DC: NIH Press, Natl Inst Drug Abuse Res Monogr Ser, 1978.
72. Fauman MA, Fauman BJ. Violence associated with phencyclidine abuse. Am J Psychiatry 1979; 136: 1584-1586.
73. File S. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Meth 1980; 2: 219-238.
74. File S, Hyde J. Can social interaction be used to measure anxiety? Br J Pharmacol 1978; 62: 19-24.
75. Fine JI, Finestone SC. Sensory disturbances following ketamine anesthesia: recurrent hallucinations. Anesth Analg 1973; 52: 428-430.
76. Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 1995; 15: 2453-2461.
77. Freed W. Glutamatergic mechanisms mediating stimulant and antipsychotic drug effects. Neurosci Biobehav Rev 1994; 18: 111-120.
78. Freed WJ. The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity. Schizophr Bull 1988; 14: 269-277.
79. Freed WJ. An hypothesis regarding the antipsychotic effect of neuroleptic drugs. Pharmacol Biochem Behav 1989; 32: 337-346.
80. Frith C, Done D. Stereotyped behaviour in madness and health. In: Cooper SJ, Dourish CT, eds. Neurobiology of Stereotyped Behaviour. Oxford Press, Clarendon 1990; 25-63.
81. Furuya Y, Kagaya T, Nishizawa Y, Ogura H. Differential effects of the strychnine-insensitive glycine site antagonist (+)-HA-966 on the hyperactivity and the disruption of prepulse inhibition induced by phencyclidine in rats. Brain Res 1998; 781: 227-235.
82. Gardner C, Guy A. A social interaction model of anxiety sensitive to acutely administered benzodiazepines. Drug Dev Res 1984; 4: 207-216.
83. Gattaz WF, Schummer B, Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm 1994; 96: 227-232.
84. Gerbaldo H, Helisch A, Schneider B, Philipp M, Benkert O. Subtypes of negative symptoms: The primary subtype in schizophrenic and non-schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 311-320.
85. Geyer MA, Braff DL. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 1987; 3: 643-668.
86. Giannini AJ, Loiselle RH, Price WA, Giannini MC. Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis. J Clin Psychiatry 1985; 46: 52-54.
87. Giannini AJ, Nageotte C, Loiselle RH, Malone DA, Price WA. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. Clin Toxicol 1984; 22: 573-579.
88. Giannini AJ, Price WA, Loiselle RH, Malone DW. Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol. J Toxicol-Clin Toxicol 1985; 23: 185-189.
89. Giardino L, Bortolotti F, Orazzo C, Pozza M, Monteleone P, Calza L, Maj M. Effect of chronic clozapine administration on [H-3]MK801-binding sites in the rat brain: A side-preference action in cortical areas. Brain Res 1997; 762: 216-218.
90. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 1997; 129: 79-84.
91. Glick SD, Cox RD, Maayani S, Meibach RD. Anticholinergic behavioral effect of phencyclidine. Eur J Pharmacol 1979; 59: 103-106.
92. Goldberg TE, Gold JM. Neurocognitive deficits in schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford: Blackwell Science Ltd., 1995; 146-162.
93. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
94. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253-273.
95. Green JF, King DJ. Cognitive functioning in schizophrenia: effects of drug treatments. CNS Drugs 1996; 6: 382-398.
96. Green MJ. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-330.
97. Greifenstein F, Yoshitake J, DeValut M, Gajewski J. A study of 1-arylcyclohexylamine for anesthesia. Anesth Analg 1958; 37: 283-294.
98. Griffith J, Cavanaugh J, Held J, Oates J. Dextroamphetamine. Arch Gen Psychiatry 1972; 26: 97-100.
99. Harborne GC, Watson FL, Healy DT, Groves L. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol 1998; 10: 134-140.
100. Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991; 337: 450-452.
101. Heresco Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-617.
102. Hirsch SR, Barnes TRE. The clinical treatment of schizophrenia with antipsychotic medication. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford: Blackwell Science Ltd., 1995; 443-468.
103. Hirsch SR, Das I, Garey LJ, de Belleroche J. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol Biochem Behav 1997; 56: 797-802.
104. Hoffman D. Typical and atypical neuroleptics antagonize MK-801-induced locomotor and stereotypy in rats. J Neural Transm 1992; 89: 1-10.
105. Holm A, Edsman I, Lundberg T, Odlind B. Tolerability of remoxipride in the long term treatment of schizophrenia. Drug Safety 1993; 8: 445-456.
106. Humphries C, Mortimer A, Hirsch S, de Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. NeuroReport 1996; 7: 2051-2055.
107. Itil T, Keskiner A, Kiremitci N, Holden J. Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J 1967; 12: 209-212.
108. Iversen SD. Interactions between excitatory amino acids and dopamine systems in the forebrain: implications for schizophrenia and Parkinson's disease. Behav Pharmacol 1995; 6: 478-491.
109. Jackson D, Johansson C, Lindgren L, Bengtson A. Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 1994; 41: 465-471.
110. Jackson JE. Phencyclidine pharmacokinetics after a massive overdose. Ann Int Med 1989; 111: 613-615.
111. Jann M, Grimsley S, Gray E, Chang W. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24: 161-176.
112. Javitt D, Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
113. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 1987; 9: 12-35.
114. Javitt DC, Sershen H, Hashim A, Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecaylamide. Neuropsychopharmacology 1997; 17: 202-204.
115. Javitt DC, Zylberman I, Zukin SR, Heresco Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151: 1234-1236.
116. Jentsch J, Redmond D Jr, Elsworth J, Taylor J, Youngren K, Roth R. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997; 277: 953-955.
117. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 1997; 17: 92-99.
118. Johansson C, Jackson DM, Svensson L. The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology 1994; 116: 437-442.
119. Johansson C, Jackson DM, Svensson L. Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology 1997; 131: 167-173.
120. Johnson KM, Hillman GR. Comparisons between phencyclidine, its monohydroxylated metabolites, and the stereoisomers of N-allyl-N-normetazocine (SKF 10047) as inhibitors of the muscarinic receptor and acetylcholinesterase. J Pharm Pharmacol 1982; 34: 462-464.
121. Johnstone M, Evans V, Baigel S. Sernyl (Cl-395) in clinical anaesthesia. Br J Anaesth 1959; 31: 433-439.
122. Jones P, Rodgers B, Murray R, Marmot M. Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994; 344: 1398-1402.
123. Jonsson L, Gunne L. Clinical studies of amphetamine psychosis. In: Costa E, Garatitini S, eds. International Symposium on Amphetamine and Related Compounds. New York: Raven Press, 1970; 929-936.
124. Kahn J, Laxenaire M, Burnat G, Albaret C, Holm A. Remoxipride in acute psychosis: intramuscular followed by oral treatment compared to haloperidol, a double-blind, multicenter trial. Hum Psychopharmacol 1994; 9: 79-92.
125. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 49: 789-796.
126. Karlsson P, Smith L, Farde L, Hsrnryd C, Sedvall G, Wiesel F. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 1995; 121: 309-316.
127. Keith VA, Mansbach RS, Geyer MA. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 1991; 30: 557-566.
128. Khot V, DeVane C, Korpi E, Venable D, Bigelow L, Wyatt R, Kirch D. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. J Clin Psychopharmacol 1993; 13: 120-127.
129. Kim JS, Kornhuber HH, Schmid BW, Holzmueller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-382.
130. King DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 1998; 8: 33-42.
131. Kornhuber HH. Chemistry, physiology and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia I. Arch Psychiatr Nervenkr 1983; 233: 415-422.
132. Kornhuber J, Kim JS, Kornhuber ME, Kornhuber HH. Chronic haloperidol administration enhances the gamma-aminobutyric acid level in the rat striatum without altering the glutamate level. Eur Neurol 1984; 23: 269-273.
133. Korpi ER, Kaufmann CA, Marnela KM, Weinberger DR. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 1987; 20: 337-345.
134. Korpi ER, Kleinman JE, Goodman SI, Wyatt RJ. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Res 1987; 22: 291-301.
135. Kramer J, Fisherman V, Littlefield D. Amphetamine abuse. JAMA 1967; 201: 89-93.
136. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
137. Kulagowski J, Broughton H, Curtis N, Mawer I, Ridgill M, Baker R, Emms F, Freedman S, Marwood R, Patel S, Ragan C, Leeson P. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity for the human dopamine D4 receptor. J Med Chem 1996; 39: 1941-1942.
138. Lathi AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
139. Laurenzana EM, Owens SM. Brain microsomal metabolism of phencyclidine in male and female rats. Brain Res 1997; 756: 256-265.
140. Lin S, Chang W, Chung M, Lam Y, Jann M. Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 1994; 34: 318-324.
141. Lindstrom E, Eriksson B, Hellgren A, Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402-412.
142. Lipska B, Swerdlow N, Geyer M, Jaskiw G, Braff D, Weinberger D. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 1995; 122: 35-43.
143. Lipska B, Weinberger D. Hippocampal damage in the neonatal rat as a model of some aspects of schizophrenia. In: Kato N, ed. The Hippocampus: Functions and Clinical Relevance. Amsterdam: Elsevier, 1996; 465-475.
144. Longson D, Deakin JFW, Benes FM. Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia. J Neural Transm 1996; 103: 503-507.
145. Luby E, Cohen B, Rosenbaum G, Gottlieb J, Kelley R. Study of a new schizophrenomimetic drug - sernyl. Am Med Ass Arch Neurol Psychiatr 1959; 81: 363-369.
146. Maayani S, Weinstein H, Ben-Zvi N, Cohen S, Sokolovsky M. Psychotomimetics as anticholinergic agents - I. 1-cyclohexylpiperidine derivatives: Anticholinesterase activity and antagonistic activity to acetylcholine. Biochem Pharmacol 1974; 23: 163-1281.
147. MacDonald JF, Bartlett MC, Mody I, Reynolds JN, Salter MW. The PCP site of the NMDA receptor complex. In: Ben-Ari Y, ed. Excitatory Amino Acids and Neuronal Plasticity. New York: Plenum Press, 1990; 27-34.
148. Maddox VH, Godefroi EF, Parcell RF. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 1965; 8: 230-235.
149. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42: 664-668.
150. Malhotra AK, Finals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impariment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150.
151. Malhotra AK, Finals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-307.
152. Mansbach RS, Geyer MA. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 1989; 2: 299-308.
153. Martin BR, Vincek WC, Balster RL. Synthesis and behavioral activity of cis-4-phenyl,4-piperidinocyclohexanol, a metabolite of phencyclidine. Subst Alcohol Actions Misuse 1981; 2: 143-147.
154. McKinney WT, Bunney WE. Animal model of depression: Review of evidence and implications for research. Arch Gen Psychiatry 1969; 21: 240-248.
155. McLaren S, Cookson JC, Silverstone T. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. Int. Clin Psychopharmacol 1992; 7: 67-72.
156. Meltzer H, Alphs L, Bastani B, Ramirez L, Kwon K. Clinical efficacy of clozapine in the treatment of schizophrenia. Pharmacopsychiatry 1991; 24: 44-45.
157. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17: 263-287.
158. Meltzer HY, Sturgeon RD, Simonovic M, Fessler RG. Phencyclidine as an indirect dopamine agonist. Psychopharmacol Bull 1980; 16: 62-65.
159. Meyer JS, Greifenstein F, Devault M. A new drug causing symptoms of sensory deprivation. J Nerv Ment Dis 1959; 129: 54-61.
160. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-1352.
161. Murray T, Horita A. Phencyclidine-induced stereotyped behavior in rats: Dose response effects and antagonism by neuroleptics. Life Sci 1979; 24: 2217-2226.
162. Neuechterlein K. Childhood precursors of adult schizophrenia. J Child Psychol 1986; 27: 133-144.
163. Noga JT, Hyde TM, Herman MM, Spurney CF, Bigelow LB, Weinberger DR, Kleinman JE. Glutamate receptors in the postmortem striatum of schizophrenic, suicide and control brains. Synapse 1997; 27: 168-176.
164. Ogawa S, Okuyama S, Araki H, Nakazato A, Otomo S. A rat model of phencyclidine psychosis. Life Sci. 1994; 55: 1605-1610.
165. Ogawa SI, Okuyama S, Araki H, Otomo S. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur J Pharmacol 1994; 263: 9-15.
166. Olney J, Farber N. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
167. Olney J, Labruyere J, Price M. Pathological changes induced by cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244: 1360-1362.
168. Olney J, Labruyere J, Wang G, Wozniak D, Price M, Sesma M. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991; 254: 1515-1518.
169. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995; 13: 335-345.
170. Owens D. Adverse effects of antipsychotic agents: Do newer agents offer advantages? Drugs 1996; 51: 895-930.
171. Pearlson G. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 1981; 148: 25-33.
172. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett 1982; 28: 81-85.
173. Petersen RC, Stillman RC. Phencyclidine: an overview. In: Petersen RC, Stillman RC, eds. National Institute of Drug Abuse Research Monograph #21. Washington, D.C: NIH Press, 1978; 1-16.
174. Porter RH, Eastwood SL, Harrison PJ. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal Glu R6 and KA2 transcripts in schizophrenia. Brain Res 1997; 751: 217-231.
175. Porter RHP, Greenamyre JT. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 1995; 64: 614-623.
176. Pradhan SN. Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 1984; 8: 493-501.
177. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP. Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 1998; 19: 434-444.
178. Rainey JM Jr, Crowder MK. Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry 1975; 132: 1076-1078.
179. Raskin A, Pelchat R, Sood R, Alphs L, Levine J. Negative symptoms assessment of chronic schizophrenia patients. Schizophr Bull 1993; 19: 627-635.
180. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D. Comparison of sernyl with other drugs: Simulation of schizophrenia performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. Arch Gen Psychiatry 1959; 1: 651-656.
181. Rothman R. PCP site 2: A high affinity MK-801-insensitive phencyclidine binding site. Neurotoxicol Teratol 1994; 16: 343-353.
182. Rothman S. Noncompetetive N-methyl-D-asparatate antagonists affect multiple ionic currents. J Pharmacol Exp Ther 1988; 246: 137-142.
183. Russell J, Greenberg B, Segal D. The Effects of phencyclidine on spontaneous aggressive behavior in the rat. Biol Psychiatry 1984; 19: 195-202.
184. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol 1995; 6: 55-65.
185. Sams-Dodd F. Automation of the social interaction test by a video tracking system: Behavioural effects of repeated phencyclidine treatment. J Neurosci Meth 1995; 59: 157-168.
186. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in the rat: A possible animal model of schizophrenia. Behav Pharmacol 1996; 7: 3-23.
187. Sams-Dodd F. Effect of novel antipsychotic drugs on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 1997; 8: 196-215.
188. Sams-Dodd F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Neurosci Rev 1998; in press.
189. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998; 19: 18-25.
190. Sams-Dodd F. A test of the predicitive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine. Neuropsychopharmacology 1998; 18: 293-304.
191. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology 1998; 135: 182-193.
192. Sams-Dodd F. Effects of selective 5-HT agonists and antagonists on PCP-induced behaviours in the rat social interaction test. Behav Pharmacol 1998; 9: 80 (abstr).
193. Sams-Dodd F. Behavioural consequences of (+)MK-801 and PCP neurotoxicity in the rat. 1999; in preparation.
194. Sams-Dodd F, Lipska BK, Weinberger DR. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 1997; 132: 303-310.
195. Sanger DJ, Joly D. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice. Psychopharmacology 1991; 104: 27-34.
196. Schlemmer R, Jackson J, Preston K, Bederka J, Garver D, Davis J. Phencyclidine-induced stereotyped behavior in monkeys: antagonism by pimozide. Eur J Pharmacol 1978; 52: 379-384.
197. Schoepp DD, Smith CL, Lodge D, Millar JD, Leander JD, Sacaan AI, Lunn WH. D,L-(Tetrazol-5-yl)glycine: a novel and highly potent NMDA receptor agonist. Eur J Pharmacol 1991; 203: 237-243.
198. Shannon HE. Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat. J Pharmacol Exp Ther 1980; 216: 543-551.
199. Shannon HE. Discriminative stimulus effects of phencyclidine: structure-activity relationships. In: Kamenka JM, Domino EF, Geneste P, eds. Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications. Ann Arbor, MI: NPP Books, 1983; 311-335.
200. Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 1991; 121: 77-80.
201. Sherman AD, Hegwood TS, Baruah S, Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry 1991; 30: 1191-1198.
202. Shulgin AT, MacLean DE. Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin Toxicol 1976; 9: 553-560.
203. Siegel R. Phencyclidine and ketamine intoxication: a study of 4 populations of recreational users. In: Peterson RC, Stillman RC, eds. National Institute of Drug Abuse Research Monograph #21. Washington, D.C.: NIH Press, 1978; 119-147.
204. Simpson MD, Slater P, Royston MC, Deakin JF. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res 1992; 42: 273-282.
205. Simpson MD, Slater P, Royston MC, Deakin JF. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 1992; 6: 41-48.
206. Singh L, Wong EHF, Kesingland AC, Tricklebank MD. Evidence against an involvement of the haloperidol-sensitive sigma recognition site in the discriminative stimulus properties of (+)-N-allylnormetazocine ((+)-SKF 10,047). Br J Pharmacol 1990; 99: 145-151.
207. Sircar R, Zukin SR. Characterization of specific sigma opiate/phencyclidine (PCP)-binding sites in the human brain. Life Sci 1983; 33: 259-262.
208. Smith R, Biggs C, Vroulis G, Brinkman S. Effects of chronic administration of phencyclidine on stereotyped and ataxic behaviors in the rat. Life Sci 1981; 28: 1163-1174.
209. 3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 1977; 26: 1435-1439.
210. Snyder S. Amphetamine psychosis: A "model" schizophrenia mediated by catecholamines. Am J Psychiatry 1973; 130: 61-67.
211. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, Thompson RT. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 1996; 22: 597-609.
212. Steinpreis R, Kuppinger H, Panos J, Hollenberg D. Determining the source of PCP-induced social withdrawal in the rat. Soc Neurosci Abst 1994; 20: 169.
213. Steinpreis R, Sokolowski J, Papanikolaou A, Salamone J. The effects of haloperidol and clozapine on PCP-and amphetamine-induced suppression of social behavior in the rat. Pharmacol Biochem Behav 1994; 47: 579-585.
214. Sturgeon R, Fessier R, Meltzer H. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behaviour and ataxia in rats. Eur J Pharmacol 1979; 59: 169-179.
215. Swerdlow NR, Bakshi V, Geyer MA. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 1996; 279: 1290-1299.
216. Tarazi FI, Florijn WJ, Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 1996; 128: 371-379.
217. Tiedtke PI, Bischoff C, Schmidt WJ. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm 1990; 81: 173-182.
218. Toru M, Kurumaji A, Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sci 1994; 55: 1683-1699.
219. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52: 829-836.
220. Ulas J, Nguyen L, Cotman CW. Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. NeuroReport 1993; 4: 1049-1051.
221. Usiello A, Sargolini F, Roullet P, Ammassari-Teule M, Passino E, Oliverio A, Mele A. N-Methyl-D-aspartate receptors in the nucleus accumbens are involved in detection of spatial novelty in mice. Psychopharmacology 1998; 137: 175-183.
222. Vahid-Ansari F, Nakabeppu Y, Robertson G. Contrasting effects of chronic clozapine, seroquel, and haloperidol administration on FosB-like immunoreactivity in the rodent forebrain. Eur J Neurosci 1996; 8: 927-936.
223. Van Kammen D, McEnvoy J, Targum S, Kardatzke D, Sebree T, Sertindole S. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168-175.
224. Vereby K, Kogan M, Mule S. Phencyclidine-induced stereotypy in rats: effects of methadone, apomorphine, and naloxone. Psychopharmacology 1981; 75: 44-47.
225. Viguera A, Baldessarini R, Hegarty J, Kammen D, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54: 49-55.
226. Vincent JP, Cavey D, Kamenka JM, Geneste P, Lazdunski M. Interaction of phencyclidine with the muscarinic and opiate receptors in the central nervous system. Brain Res 1978; 152: 176-182.
227. Vincent JP, Kartalovski B, Geneste P, Kamenka JM, Lazdunski M. Interaction of phencyclidine ("angel-dust") with a specific receptor in rat brain membranes. Proc Natl Acad Sci USA 1979; 76: 4678-4682.
228. Wall ME, Brine DR, Jeffcoat AR, Cook CE. Phencyclidine metabolism and disposition in man following a 100mg intravenous dose. Res Comm Subst Abuse 1981; 2: 161-172.
229. Weinberger D, Lipska B. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: In search of common ground. Schizophr Res 1995; 16: 87-110.
230. Weiner I, Feldon J. Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia. Pharmacol Biochem Behav 1992; 42: 625-631.
231. Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991; 29: 41-54.
232. Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology, results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 1995; 119: 231-238.
233. White IM, Flory GS, Hooper KC, Speciale J, Banks DA, Rebec GV. Phencyclidine-induced increases in striatal neuron firing in behaving rats: reversal by haloperidol and clozapine. J Neural Transm 1995; 102: 99-112.
234. Wiley JL. Clozapine's effects on phencyclidine-induced disruption of prepulse inhibition of the acoustic startle response. Pharmacol Biochem Behav 1994; 49: 1025-1028.
235. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: A realistic animal model of depression. Neurosci Biobehav Rev 1992; 16: 525-534.
236. 3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 1988; 50: 274-281.
237. Wong LK, Bieman K. Metabolites of phencyclidine in humans. Biomed Mass Spect 1975; 2: 204-205.
238. Wright HH, Cole EA, Batey SR, Hanna K. Phencyclidine-induced psychosis: eight-year follow-up of ten cases. South Med J 1988; 81: 565-567.
239. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994; 14: 4159-4166.
240. Young T, Lawson GW, Gacono CB. Clinical aspects of phencyclidine (PCP). Int J Addiction 1987; 22: 1-15.
241. Zhou GZ, Katki AG, Schwartz S, Munson PJ, Rodbard D. Quantitative characterization of multiple binding sites for phencyclidine and N-allylnormetazocine in membranes from rat and guinea pig brain. Neuropharmacology 1991; 30: 775-786.
242. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782-791.
243. 3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1976; 10: 5372-5376.